Clinical trial · Observational
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients Presenting to a Tertiary Care Hospital of Karachi, Pakistan: A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This will be the first in-depth study to evaluate pretreatment and 12 months post-treatment, neurocognitive and psychological outcomes of children with brain tumor and blood cancer in Pakistan. The investigators will also determine the socioeconomic burden of pediatric brain tumors in low middle-income region and the association of micro RNA and protein markers with neurocognitive outcomes in PBT and blood cancer children. A prospective cohort study with a follow-up of 12 months at the Aga Khan University Hospital, Karachi, Pakistan and Jinnah postgraduate Medical Centre , Karachi, Pakistan will be conducted. After taking consent/ assent the investigators will recruit 80, 5-21 years old children with newly diagnosed brain tumors presenting with any stage, who have not undergone any treatment. Trained psychologist will assess the neurocognitive outcomes by the Slosson scale, Raven's progressive matrices and Wechsler Intelligence Scale for children (WISC V) and Wechsler Adult Intelligence Scale (WAIS-IV) tools. The Quality of life and depression of the children will be determined by PedQL and Revised Children's Anxiety and Depression Scale (RCADS) and hospital anxiety and depression scale (HADs) respectively . The financial burden of the disease on the family will be measured on a visual analog scale ranging from no burden (0) to very large burden (100) and the parents QoL and disrupted schedule, financial problems, lack of family support, health problems and the impact of caregiving on caregiver's self-esteem will be assessed by Pediatric Quality of Life Inventory PedQl (family module) and Caregiver Reaction Assessment (CRA) tools respectively. The serum micro RNA (mi-21, mi-10b and mi-210) and protein markers (GFAP, NSE and S100β) will be assessed by qRT-PCR and ELISA.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Cancer | Liquid Tumor | ALIAS | 0.90 |
| Brain Tumor, Pediatric | Childhood Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neurocognitive tools | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Pediatric brain tumor patients
- description
- The study participants will be 5 to 21 years old children with newly diagnosed brain tumors presenting with any stage, who have not undergone any treatment
- interventionNames
- Behavioral: Neurocognitive tools
- label
- Blood cancer children
- description
- The study participants will be 5 to 21 years old children with newly diagnosed blood cancer presenting with any stage, who have not undergone any treatment
- interventionNames
- Behavioral: Neurocognitive tools
Primary outcomes (5)
- measure
- Neuro-cognitive outcomes
- timeFrame
- November 2020 to November 2023
- description
- The Verbal component of neurocognition will be assessed by slosson scale.A higher score means a better outcome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: 1. 5-21 years children with brain tumor, presenting with any stage 2. Children residing in Pakistan for at least 3 months. 3. Children accompanied by both or either of the parent 4. Children with basic understanding of English 5. Children and their parents who understand and speak in Urdu 6. Children and their parents who will give assent / consent to participate in the study Exclusion Criteria: 1. Children who have received any type of treatment for brain tumor and blood cancer 2. Children presenting with recurrence 3. Children with metastatic brain tumor and blood cancer 4. Known cases of any illness leading to psychiatric/neurological illness (e.g. ADHD, autism, schizophrenia) as confirmed by medical records, will be excluded from the study as they may be on medications that might distort the results. 5. Children with physical comorbidities and debilitating disease 6. Children who will loss to follow-up \-
References
Publications (1)
- DERIVEDZahid N, Enam SA, Martensson T, Azam I, Mushtaq N, Moochhala M, Javed F, Kausar F, Hasan A, Rehman L, Mughal MN, Altaf S, Kirmani S, Brown N. Predictors of neurocognition outcomes in children and young people with primary brain tumor presenting to tertiary care hospitals of Karachi, Pakistan: a prospective cohort study. Childs Nerv Syst. 2024 Jun;40(6):1707-1719. doi: 10.1007/s00381-024-06306-x. Epub 2024 Feb 16. PMID 38363314